Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

Evaluating Gingivitis and Systemic Biomarkers

NCT06962956 · View on ClinicalTrials.gov ↗

Study Summary

This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is to assess the causal effect of oral hygiene intervention on gingivitis and systemic biomarkers.

Conditions Studied

Interventions

  • DRUG 0.76% Sodium Monofluorophosphate Dentifrice
  • DRUG 0.454% Stannous Fluoride Dentifrice

Study Locations (1)

Indiana

  • Salus Research — Fort Wayne

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2025-04-30
Est. Completion 2025-10-31
Phase Phase 1

Sponsor

Procter and Gamble

25 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06962956

The ClinicalTrials.gov registry entry for NCT06962956 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procter and Gamble, which has 25 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Gingivitis appearing as the primary indexed condition, and to 2 interventions — of which 0.76% Sodium Monofluorophosphate Dentifrice is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06962956 reports 1 study location spanning 1 distinct geographic area — top geographies include Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06962956 about?

NCT06962956 is a clinical study titled "Evaluating Gingivitis and Systemic Biomarkers". This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is...

What is the current status of trial NCT06962956?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2025-04-30. Estimated completion is 2025-10-31.

What conditions does trial NCT06962956 study?

This clinical trial studies the following conditions: Gingivitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06962956?

The interventions under investigation include: 0.76% Sodium Monofluorophosphate Dentifrice (DRUG), 0.454% Stannous Fluoride Dentifrice (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06962956?

This trial is sponsored by Procter and Gamble, which has 25 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06962956 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial